{"id":"W3165865880","doi":"10.1136/annrheumdis-2021-eular.960","title":"AB0532 MAINTENANCE OF RESPONSE THROUGH 5 YEARS OF CONTINUOUS GUSELKUMAB TREATMENT: RESULTS FROM THE PHASE-3 VOYAGE 1 TRIAL","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"Pfizer; Eli Lilly and Company","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Internal medicine; Adalimumab; Clinical trial; Clearance; Randomized controlled trial; Surgery; Immunology; Urology; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00285974,0.001206446,0.003270418,0.0003313838,0.0004949102,0.001622719,0.001017702,0.001678088,0.004080529],"category_scores_gemma":[0.001890808,0.000364432,0.003146606,0.0004826491,0.00116371,0.001798123,0.0005093771,0.004698905,0.00133155],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001027851,"about_ca_system_score_gemma":0.0010785,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008681158,"about_ca_topic_score_gemma":0.001433512,"domain_scores_codex":[0.9989619,0.0004706038,0.00004554203,0.0001394478,0.00007045108,0.0003120153],"domain_scores_gemma":[0.9983521,0.0004694738,0.0003454286,0.0002106185,0.00007902465,0.0005434515],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8646247,0.009262878,0.002799756,0.0008336917,0.002337121,0.000123712,0.0002008603,0.001570194,0.007384455,0.0003402416,0.002780031,0.1077423],"study_design_scores_gemma":[0.7253486,0.237395,0.02860388,0.0002007735,0.001386853,0.0002702483,0.0001362057,0.001291808,0.001457965,0.0007309527,0.003116726,0.00006098594],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872974,0.008368745,0.0004001762,0.0008100416,0.0003054075,0.0003913586,0.000873454,0.0001081881,0.001445314],"genre_scores_gemma":[0.9929754,0.002309484,0.0005245462,0.0008682464,0.0002042293,0.0004750602,0.001228697,0.00003185256,0.001382564],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004080529,"threshold_uncertainty_score":0.01512396,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1498465969173492,"score_gpt":0.4241457042358771,"score_spread":0.2742991073185279,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}